Back of the Eye Disorders Markets, 2030

Wednesday, 21. February 2018 10:37

Dublin, Feb. 21, 2018 (GLOBE NEWSWIRE) -- The "Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030" report has been added to ResearchAndMarkets.com's offering.

Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050. In fact, chronic eye diseases are considered to be one of the main causes of vision loss globally, and an estimated 90% cases of visual impairment are reported to be caused due to such conditions. It is worth highlighting that a significant portion of these chronic ophthalmological disorders are clinical conditions related to the back of the eye.

The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster drugs, such as Lucentis and Eylea, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks that have an adverse impact on their therapeutic potential and adoption. Further, there are no treatment approaches available for a number of ophthalmological indications, such as dry age related macular degeneration (dry AMD), retinitis pigmentosa (RP) and leber congenital amaurosis.

In order to overcome these challenges, various stakeholders are engaged in the development of novel therapeutic approaches. With the entry of several start-ups that are driving the innovation in this domain, the pipeline has several novel product candidates in various stages of development. Companies are steadily collaborating to develop and commercialize their products globally, in-license intellectual property to design new treatment modalities and advance research initiatives in this domain.

The Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030' report features an extensive study of the market for novel drugs, drug-device combinations and technologies for the treatment of back of the eye disorders. The focus of this study is on the applications and the likely evolution of novel treatment options (excluding steroids and corticosteroids) in the mid to long term.

The evolving market has its hopes pinned on the efforts of multiple start-ups, small and large-sized companies. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of novel drugs, providing information on various drug / therapy developers, phase of development (clinical, preclinical or discovery stage) of product candidates, information on drug class, molecular target, type of therapy, mechanism of action, route of administration, and key therapeutic indication(s). In addition, we have provided a list of drug device combinations that target the back of the eye.
  • A world map representation, depicting the most active geographies in terms of the presence of companies developing drugs to treat back of the eye disorders.
  • A bull's eye analysis highlighting distribution of pipeline candidates in terms of phase of development, type of target and drug class. A grid analysis based on type of drug class developed / being developed across different indications and stages of development.
  • An elaborate discussion on lifecycle management strategies, depicting how companies are using various methods to expand patent exclusivity in order to exploit the revenue generation potential of their proprietary products.
  • Comprehensive profiles of clinical stage (phase II/III and above) drug candidates specifically targeting back of the eye disorders, highlighting their current status of development, mechanism of action, technology, patent portfolio, clinical trial information and recent developments.
  • A review of currently available technologies and delivery systems that are being used to administer therapeutics to the back of the eye, featuring brief profiles of the various technical advances, key benefits offered and information on the product candidates pipeline that are based on these technologies.
  • A discussion on various visual prosthesis that are available, highlighting their mechanism of action. In addition, we have provided a comparative 2X2 analysis of the different types visual prosthesis based on supplier power and product competitiveness.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, manufacturing and services agreements, and other relevant agreements.
  • A discussion on the key promotional strategies that have been adopted for marketing approved drugs, namely (based on the approval year) Macugen, Lucentis, Eylea and Jetrea, that are presently prescribed to treat back of the eye disorders.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. To account for the uncertainties associated with the development of novel drugs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Background and Context
3.2. Structure of the Eye
3.3. Components of Back of the Eye
3.4. The Visual Cycle
3.5. Barriers to the Back of the Eye
3.6. Route of Administration of Drugs to Back of the Eye
3.7. Disorders Associated with Back of the Eye
3.8. Treatment Options for Back of the Eye Disorders
3.9. Drug Delivery Platforms for Back of the Eye Disorders

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Back of the Eye Disorders: Clinical Pipeline
4.3. Back of the Eye Disorders: Preclinical/Discovery Pipeline
4.4. Back of the Eye Disorders Pipeline: Leading Players
4.5. Back of the Eye Disorders Pipeline: Most Prominent Hubs
4.6. Back of the Eye Disorders Pipeline: Regional Landscape
4.7. Back of the Eye Disorders Pipeline: Grid Analysis

5. PRODUCT LIFE CYCLE MANAGEMENT STRATEGIES
5.1. Introduction
5.2. Macugen
5.3. Lucentis
5.4. Eylea
5.5. Jetrea
5.6. Conbercept

6. DRUG PROFILES
6.1. Chapter Overview
6.2. LUXTURNA (Spark Therapeutics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.3. Sirolimus (Santen Pharmaceutical): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.4. Abicipar Pegol (Molecular Partners/Allergan): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.5. Brolucizumab (Alcon, a Division of Novartis): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.6. GS010 (GenSight Biologics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.7. Lampalizumab (Roche): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.8. Optina (Ampio Pharmaceuticals): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.9. Squalamine (OHR Pharmaceutical): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.10. Zuretinol (Novelion Therapeutics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
6.11. Zimura (Ophthotech): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results

7. MARKET SIZE AND OPPORTUNITY ANALYSIS
7.1. Chapter Overview
7.2. Forecast Methodology and Key Assumptions
7.3. Overall Back of the Eye Disorders Market, 2017-2030
7.4. Back of the Eye Disorders Market: Distribution by Indications
7.5. Back of the Eye Disorders Market: Distribution by Drug Class
7.6. Back of the Eye Disorders Market: Distribution by Mechanism of Action
7.7. Back of the Eye Disorders Market: Distribution by Route of Administration

8. TECHNOLOGY PLATFORMS, DELIVERY SYSTEMS AND DRUG DEVICE COMBINATIONS
8.1. Chapter Overview
8.2. Drug Formulation Technologies
8.3. Drug Delivery Technologies/Systems
8.4. Drug Device Combinations/Implants

9. VISUAL PROSTHESIS
9.1. Chapter Overview
9.2. Visual Prosthesis/Bionic Eye


10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Back of the Eye Disorders: List of Partnerships
10.4. Back of the Eye Disorders: Partnerships Analysis

11. PROMOTIONAL ANALYSIS
11.1. Chapter Overview
11.2. Channels Used for Promotional Campaigns
11.3. Summary: Product Website Analysis
11.4. Promotional Analysis: Macugen
11.5. Promotional Analysis: Lucentis
11.6. Promotional Analysis: Eylea
11.7. Promotional Analysis: Jetrea

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats

13. CONCLUSION
13.1. The Back of the Eye Disorders Market is Characterized by a Robust Pipeline of Candidates Belonging to Different Drug Classes
13.2. Although Product Candidates are Being Developed to Treat a Number of Clinical Conditions, the Primary Focus is on Macular Degenerative Disorders
13.3. Increasing Partnerships Activity to Support Drug Development is Indicative of Future Opportunity
13.4. Currently, the Market is Led by Big Pharma Players; Many Start-ups, Though, are Making Significant Strides in this Domain
13.5. Multiple Novel Delivery Approaches are Being Investigated to Assist in Improving Patient Compliance
13.6. Given the Presence of Blockbuster Drugs, and Several Late Stage Product Candidates, the Market is Poised to Grow Steadily in the Foreseen Future

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Elise Brownell, Senior Vice President of Operations and Project Management, Amarantus Bioscience
14.3. Quinton Oswald, President and CEO, Neurotech Pharmaceuticals
14.4 Samantha Cobb, CEO, AdAlta

15. APPENDIX: LIST OF DISCONTINUED MOLECULES

16. APPENDIX: TABULATED DATA

17. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

  • 4D Molecular Therapeutics
  • AbbVie
  • Academy of Finland
  • Accredo Health Group
  • Achillion Pharmaceuticals
  • Aciont
  • ActiveSite Pharmaceuticals
  • Acucela
  • AdAlta
  • Adverum Biotechnologies
  • Aegerion Pharmaceuticals
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Affilogic
  • AGTC
  • Alcon (a Novartis division)
  • Alfred Hospital
  • Alimera Sciences
  • Alkeus Pharmaceuticals
  • Allegro Ophthalmics
  • Allergan
  • Allinky Biopharma
  • ALTEOGEN
  • Amarantus BioScience
  • Amarna Therapeutics
  • Ampio Pharmaceuticals
  • Amyndas Pharmaceuticals
  • Apellis Pharmaceuticals
  • Apexian Pharmaceuticals
  • Apexigen
  • Apollo Endosurgery
  • Appletree CI Group
  • Araim Pharmaceuticals
  • Ascendis Pharma
  • AsclepiX Therapeutics
  • Astellas Institute for Regenerative Medicine (AIRM)
  • Astellas Pharma
  • Athena Vision
  • AyuVis Research
  • Bascom Palmer Eye Institute
  • Bausch + Lomb
  • Bayer
  • BCM Families Foundation
  • Benitec Biopharma
  • Besse Medical
  • Bicycle Therapeutics
  • BIOCND
  • Biogen
  • BioInvent
  • Biokine Therapeutics
  • BioLight Lifesciences
  • Bionic Sight
  • Bionic Vision Technologies (BVT)
  • BIOPHYTIS
  • BioTime
  • Biovista
  • Case Western Reserve University (CWRU)
  • Catalent
  • Catalyst Biosciences
  • Universit catholique de Louvain
  • Cellular Dynamics International (CDI)
  • Ceregene
  • Charlesson
  • Chengdu Kanghong Pharmaceuticals Group
  • Children's Hospital of Philadelphia
  • Cipla BioTec
  • Clanotech
  • Clearside Biomedical
  • Clonz Biotech
  • Coherus Biosciences
  • Columbia University
  • CoMentis
  • Copernicus Therapeutics
  • Critical Pharmaceuticals
  • CuraScript SD
  • CVS Caremark
  • Daiichi Sankyo
  • DelSiTech
  • Domp
  • Editas Medicine
  • Eleven Biotherapeutics
  • ElsaLys Biotech
  • Envisia Therapeutics
  • Exonate
  • EyeGate Pharma
  • Eyemedics
  • Eyetech Pharmaceuticals
  • Eyevensys
  • Ferrer
  • Fondation Voir et Entendre
  • Formycon
  • ForSight VISION 4
  • Foundation Fighting Blindness (FFB)
  • FUJIFILM Holdings
  • Galapagos
  • Galaxy Ophthalmics
  • Gemini Therapeutics
  • Genable Technologies
  • Gene Signal
  • Gene Techno Science
  • Genaera Corporation
  • Genentech
  • Genethon
  • GenSight Biologics
  • Gilead Sciences
  • Graybug Vision
  • Grey Innovation
  • GlaxoSmithKline (GSK)
  • Gunma University
  • Hadassah Medical Center
  • Hanmi Pharmaceutical
  • Harvard Medical School (HMS)
  • Healios
  • Hemera Biosciences
  • Henogen (a subsidiary of the Novasep group)
  • HORAMA
  • Huabo Biopharm
  • i2 Pharmaceuticals
  • Ichor Therapeutics
  • Icon Bioscience
  • Iconic Therapeutics
  • Illinois Institute of Technology
  • Inception Sciences
  • InFlectis BioScience
  • InnoCore Pharma
  • Innovent Biologics
  • Intas Pharmaceuticals
  • Intrexon
  • Ionis Pharmaceuticals
  • I'rom Group
  • Ixchel Pharma
  • Janssen
  • jCyte
  • Jeil Pharmaceutical
  • Jiangsu T-mab BioPharma
  • Johns Hopkins University
  • K.N. Toosi University of Technology
  • Kala Pharmaceuticals
  • Kalos Therapeutics
  • KalVista Pharmaceuticals
  • KMG Pharma
  • Kodiak Sciences
  • Kowa Company
  • Laboratoire de Gntique Mdicale de Strasbourg
  • LeadArtis
  • Lin Bio Science
  • Lonza
  • Loyola University Chicago
  • Lpath
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology (MIT)
  • McKesson
  • Medical College of Wisconsin (MCW)
  • MeiraGTx
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • MimeTech
  • Mimetogen Pharmaceuticals
  • MiniFAB
  • Mitotech
  • Molecular Partners
  • Monash University
  • MorphoSys
  • Mosaic Biosciences
  • M's Science Corporation
  • Mystic Pharmaceuticals
  • Nano Retina
  • Nanovision
  • National Institutes of Health (NIH)
  • Nektar Therapeutics
  • Neovacs
  • Neurotech Pharmaceuticals
  • NeXstar Pharmaceuticals
  • Novartis
  • Novelion Therapeutics
  • Ocata Therapeutics
  • OccuRx
  • Ocugen
  • Ocular Therapeutix
  • Oculis
  • OcuNexus Therapeutics
  • Odylia Therapeutics
  • Ohr Pharmaceutical
  • OliX Pharmaceuticals
  • Omeros
  • Opthea
  • Ophthotech
  • Opsis Therapeutics
  • Optobionics
  • Casey Eye Institute, Oregon Health & Science University (OHSU)
  • Osaka University
  • Oxford BioMedica
  • Oxular
  • Paloma Pharmaceuticals
  • Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse
  • PanOptica
  • Patheon
  • Pfenex
  • Pfizer
  • Pieris Pharmaceuticals
  • Pixium Vision
  • Polus
  • PolyActiva
  • Potentia Pharmaceuticals
  • Preceyes
  • ProLynx
  • Promedior
  • ProQR
  • Proretina Therapeutics
  • Proteostasis Therapeutics
  • pSivida
  • Qilu Pharmaceuticals
  • Quark Pharmaceuticals
  • Ra Pharma
  • Recursion Pharmaceuticals
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • Reliance RX
  • ReNeuron
  • Replenish
  • Retina Foundation of the Southwest
  • Retina Implant
  • Retinagenix
  • RetroSense Therapeutics
  • Ribomic
  • Roche
  • Royal DSM
  • RWTH Aachen University
  • RXi Pharmaceuticals
  • Saksin Lifesciences
  • Samsung Bioepis
  • SanBio
  • Sanofi
  • Santen Pharmaceuticals
  • Santhera Pharmaceuticals
  • Santo Holding
  • SciFluor Life Sciences
  • Second Sight
  • Selexis
  • SENJU Pharmaceutical
  • SENS Research Foundation
  • SGS Life Science
  • Shanghai Jiao-Tong University
  • Sonikure Technology
  • Spark Therapeutics
  • Stanford University
  • Stealth BioTherapeutics
  • Sumitomo Dainippon Pharma
  • Sun Pharmaceutical
  • Syracuse University
  • Taiwan Liposome Company
  • Tanox
  • Massachusetts Eye and Ear Infirmary
  • The University of Manchester
  • University of Massachusetts Medical School
  • University of Pennsylvania
  • TheraKine
  • ThromboGenics
  • TRACON Pharmaceuticals
  • University of Tbingen
  • Tyrogenex
  • UCL Business
  • Universal Cells
  • University License Equity Holding (ULEHI), University of Colorado
  • University of California
  • University of Melbourne
  • University of Pittsburgh Medical Center (UPMC)
  • University of Utah
  • University of Virginia School of Medicine
  • VAXIER THERAPEUTICS
  • Versant Ventures
  • Verseon
  • VESSL Therapeutics
  • Vision Medicines
  • Vision Technologies
  • Walgreens Specialty Pharmacy
  • Wellstat Ophthalmics Corporation
  • WuXi AppTec
  • Xbrane Biopharma
  • XL Vision Sciences



For more information about this report visit https://www.researchandmarkets.com/research/4f6nzh/back_of_the_eye?w=12

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.



CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Optical Disorders Drugs

Primary Logo

Related Links: 
Author:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.